Despite changes, generics continue to face obstacles in Japan

05/21/2013 | BioSpectrum Asia

Although Japan is the world's second-largest pharmaceutical market after the U.S., generics represent only 6.6% of prescription drug sales, largely because of public attitudes skeptical of the effectiveness and safety of unfamiliar brands, especially if the drugs are produced in countries such as India and China. Several factors may help change these views: government efforts to further cut generic-drug prices, higher reimbursements for generics, patent expirations and a rapidly aging population.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA